Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will report first quarter 2026 financial results on May 7, 2026 before the market opens. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Access the live webcast via the company Events page and use the dial-in to ask questions; an archived webcast will be posted after the call.
Lexicon (NASDAQ:LXRX) will present Phase 2b and preclinical data at the American Academy of Neurology Annual Meeting, April 18-22, 2026 in Chicago.
Key points: PROGRESS data support selection of pilavapadin 10 mg for Phase 3 in diabetic peripheral neuropathic pain after a nominally significant reduction in Average Pain at Week 8 and concordant improvements in Worst and Least Daily Pain. The 10 mg dose was generally well-tolerated over 8 weeks. Lexicon will also present preclinical spasticity data on April 20.
Lexicon (Nasdaq: LXRX) announced three sotagliflozin presentations at the American College of Cardiology Annual Meeting, March 28-30, 2026 in New Orleans. Data include a prespecified SCORED analysis showing reductions in heart failure and MACE across BMI strata and SOTA-P-CARDIA results showing improved quality of life and reduced epicardial adipose tissue in non‑diabetic HFpEF.
Presentations occur March 28: two SOTA-P-CARDIA posters on symptoms/function and fat reduction, and a SCORED poster on BMI-stratified efficacy.
Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1 study of LX9851, an oral non-incretin candidate for obesity.
Lexicon earned a second $10 million milestone in 2026, may earn a third this year, and is eligible for up to $1 billion in total payments plus tiered royalties. The 96-subject trial is expected to complete in Q1 2027.
Lexicon (NASDAQ: LXRX) will present post hoc clinical data on sotagliflozin at ATTD on March 12, 2026, assessing kidney function's effect on one-year efficacy and safety in type 1 diabetes.
Using pooled 52-week placebo-controlled trials, sotagliflozin (200 mg, 400 mg) improved HbA1c, body weight, systolic blood pressure and reduced total insulin use and clinically important hypoglycemia in patients with normal and mildly reduced kidney function; effects were less pronounced in CKD Class 3A. Lexicon plans an NDA resubmission for ZYNQUISTA (sotagliflozin) in 2026.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Total revenues were $5.5M Q4 and $49.8M FY2025, net loss was $15.5M Q4 and $50.3M FY2025, and cash was $125.2M at year-end.
Key pipeline milestones: SONATA-HCM >50% enrolled, expected topline Q1 2027; NDA resubmission for T1D planned in 2026 if STENO1 data meet FDA requirements; pilavapadin cleared for Phase 3 by FDA End-of-Phase 2. In Feb 2026 Lexicon received >$100M in new cash including ~$96.7M equity proceeds and a $10M Novo Nordisk milestone.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will participate in three investor events in March 2026. Management will speak at a Leerink Partners fireside chat on March 11, 2026 at 10:00 a.m. and hold 1x1 meetings at Jefferies Biotech on the Beach and Barclays Global Healthcare, March 10–12.
According to the company, a live recording and replay of the Leerink fireside chat will be available via the company Events page.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Investors can access the live webcast and archived replay on the company Events page; registered participants may receive dial-in numbers and a unique PIN to ask questions.
Lexicon Pharmaceuticals (Nasdaq: LXRX) closed an underwritten public offering of 32,000,000 common shares at $1.30 per share and a concurrent private placement of 22,400,000 common shares plus 367,145 Series B convertible preferred shares at $65 per preferred share on February 2, 2026.
Lexicon granted underwriters a 30-day option to buy up to 4,800,000 additional common shares and an Invus affiliate an option to buy up to 94,855 additional preferred shares (convertible into 4,742,744 common shares). Net proceeds are intended for R&D, working capital, and general corporate purposes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) priced a public offering of 32,000,000 common shares at $1.30 per share for expected gross proceeds of $41.6 million, closing on or about Feb 2, 2026. Underwriters have a 30-day option for an additional 4,800,000 shares.
Concurrently, Lexicon agreed a private placement to an affiliate of Invus for approximately $41.1 million including common shares and Series B convertible preferred stock convertible into common shares. Proceeds are for R&D, working capital and general corporate purposes.